Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Cipla is one of India's largest pharmaceutical companies, with leadership in respiratory therapies (inhalers), anti-infectives and urology in the domestic branded-generics market, and a historically pioneering role in affordable HIV antiretrovirals. Its key markets are India, North America (complex generics including respiratory and peptide products) and South Africa, where it is a top-tier player. Revenue is driven by chronic-therapy branded generics in India and limited-competition launches in the US.
It is consistently among the top three players in the Indian pharmaceutical market by domestic sales.
Cipla Ltd. is a constituent of NIFTY 100, NIFTY 200, NIFTY 50, NIFTY 500, NIFTY HEALTHCARE, NIFTY PHARMA. See where it sits on the market heatmap →
Consolidated annual figures taken from Cipla Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 48.03 | 65.29 | 51.05 |
| Book value / share (₹) | 427.34 | 387.43 | 331.98 |
| Return on equity | 11.2% | 16.9% | 15.4% |
| Return on capital employed | 13.2% | 18.9% | 19.1% |
| Operating margin | 16.6% | 21.9% | 20.3% |
| Net margin | 13.7% | 19.1% | 16.1% |
| EBITDA | ₹5,883 Cr | ₹7,128 Cr | ₹6,291 Cr |
| Free cash flow | ₹861 Cr | ₹3,457 Cr | ₹2,785 Cr |
| Total debt | ₹258 Cr | ₹92 Cr | ₹247 Cr |
| Debt to equity | 0.01 | 0.00 | 0.01 |
| Interest coverage | 85.9 | 97.1 | 58.3 |
| Current ratio | 3.44 | 4.24 | 3.70 |
| Shares outstanding | 80,78,00,000 | 80,76,00,000 | 80,73,50,000 |
Open the full income statement, balance sheet and cash flow for CIPLA →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.